Clinical Study Results
cover?
1. Study Name
Title of the Study: A Phase 3, Multicenter, Randomized, Placebo-controlled,
Double-blind Study of the Efficacy and Safety of Apremilast
(CC-10004) in Subjects With Mild to Moderate Plaque
Psoriasis
Brief Title: Apremilast as a Direct Treatment for Mild-to-Moderate
Plaque Psoriasis Versus Placebo: an Analysis of Clinical
Safety and Efficacy (ADVANCE)
Protocol Number: CC-10004-PSOR-022 (20200061)
EU Trial Number: Not applicable
Other Identifiers: NCT03721172
Date of This 17 February 2021
Summary:
What does this summary cover?
This summary shows the main results from one clinical study. The results are only
for this study. Other studies may find different results. Researchers and health
authorities look at the results of many studies to decide which medicines work best
and are safest for participants.
Amgen has committed to make research results available to the public. This
summary has been provided as part of that commitment and should not be used for
any other purpose. It should not be considered to make a claim for any product or to
guide treatment decisions.